QUEBEC CITY, QC, May 15 /CNW/ - Medicago Inc. (TSX-V: MDG), a
biotechnology company focused on developing highly effective and affordable
vaccines based on proprietary manufacturing technologies and Virus-Like
Particles (VLPs), today announced it received the 2009 Genesis "Innovation"
award at gala presented by BIOQuebec on May 14, 2009, in Montreal, Quebec. The
Genesis Awards recognize outstanding achievements by companies that play a key
role in the growth of Quebec's biotech, health technology and life sciences
"We are pleased to have received yet another industry award which
highlights our innovation behind the utilization of plants and VLPs for the
production of vaccines," said Andy Sheldon, President and CEO of Medicago. "As
we transition to a clinical company this year, we are proud that our mission
to develop highly effective vaccines, rapidly and cost effectively, has been
recognised through this award."
Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.
Forward Looking Statements
This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release
For further information:
For further information: Medicago, Inc.: Andy Sheldon, President and
CEO, (418) 658-9393; Medicago Inc.: Arianna Vanin, Director, Investor
Relations, (514) 796-3993